A-834,735
# A-834,735

A-834,735 is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist at both the $CB_1$ and $CB_2$ receptors, with a $K_i$ of 12 nM at $CB_1$ and 0.21 nM at $CB_2.$ Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group of A-834,735 and related compounds imparts significant selectivity for $CB_2,$ with most compounds from this group found to be highly selective $CB_2$ agonists with little affinity for $CB_1.$ However, low nanomolar $CB_1$ binding affinity is retained with certain heterocyclic 1-position substituents such as (N-methylpiperidin-2-yl)methyl (cf. AM-1220, AM-1248), or the (tetrahydropyran-4-yl)methyl substituent of A-834,735, resulting in compounds that still show significant affinity and efficacy at both receptors despite being $CB_2$ selective overall.

## Legal status

As of October 2015 A-834,735 is a controlled substance in China.

